The Journal for ImmunoTherapy of Cancer (JITC) received its first impact factor of 8.374! JITC’s impact factor ranks in the top 8 percent of all journals published in the categories of oncology and immunology.
Submit an abstract to the 33rd Annual Meeting or presentation application to the Immune Escape program by 5 p.m. PDT on Aug. 1, 2018!
SITC Cancer Immunotherapy Guidelines – Cutaneous Melanoma Webinar on July 30 Join SITC experts to discuss immunotherapy treatment standards for melanoma on the recently updated clinical guidelines manuscript in a free webinar at 6 p.m. ET on July 30.
"An update on the Society for Immunotherapy of Cancer consensus statement on tumor immunotherapy for the treatment of cutaneous melanoma: version 2.0"
The Society for Immunotherapy of Cancer’s new online activity explains cancer immunotherapy and the immune system to patients.
See members discuss the benefits of a SITC membership in this new video.
SITC members who purchase Cancer Immunotherapy Principles and Practice receive a 20 percent discount and free shipping with a promo code.*
*Available only when ordering from Demos Medical Publishing. Cannot be combined with any other offers.
Explore resources and educational opportunities for cancer patients and those who advocate for them.
Track the latest advancements and educational opportunities in cancer immunotherapy and immunology.
Advance science, submit your manuscript and monitor the global progress of cancer immunotherapy research.
This two day program is divided into a lectures series presented by world class scientists in the field of immuno-oncology, and a hands-on workshop laboratory to explore the optimization and troubleshooting of Opal staining, multispectral image acquisition ...
Currently scfvs, antibody-derived single chain variable fragment based CAR to target CD19 antigen is the most common CAR strategy clinically used. But based on the cited article, tumor cells can be targeted also through use of non-antibody based approahes.This ...
Dear Dr. Ramakrishna, Below please find a short summary of immunotherapies targeting CD123, CD33. All can be found on clinicaltrials.gov. I have heard that the City of Hope (COH) CAR T cells anti-CD123 study is showing early promise, but I have no ...
Donate today to support early career scientists who are emerging leaders seeking to advance research in the cancer immunotherapy field.
An open access, peer-reviewed journal, the Journal for ImmunoTherapy of Cancer (JITC) is the global voice of the society, producing original research articles, literature reviews and more on tumor immunology and cancer immunotherapy.
It is the mission of the Society for Immunotherapy of Cancer (SITC) to improve cancer patient outcomes by advancing the science, development and application of cancer immunology and immunotherapy through our core values of interaction/integration, innovation, translation and leadership in the field. SITC aims to make cancer immunotherapy a standard of care and the word “cure” a reality for cancer patients everywhere.
Tel: +1 414 271 2456 | Fax: +1 414 276 3349 | Email: email@example.com